Extract from half yearlyVery worrying.Business risks Limited...

Extract from half yearly

Very worrying.

Business risks Limited Cash
The Company will have to raise more money to finance technology development, commercialisation and deployment of its products and other longer-term objectives. Such fundraising may dilute Shareholders, may be on terms unfavourable to the Company or may not be available at all. Early-Stage Business The Companyís business operations are at an early stage, and the commercialisation of HeraCARE has not yet been proven at scale. The Companyíssuccess will depend on the Companyís ability to implement its business plan, the ability to commercialise
the Companyís products and the ability of the Company to successfully implement its R&D plans. Competition
There can be no assurance that the Company will be able to match or compete with the efforts or funding of competitors that release competing products to market. HeraMED is focussed on maintaining and developing strong relationships with health
care providers, being able to innovate and respond to changing market need